Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -9.50% | -6.29% | -- |
| Total Revenue | -- | -- | -9.50% | -6.29% | -- |
| Cost of Revenue | -14.64% | -38.45% | 27.99% | 30.14% | -42.49% |
| Gross Profit | 47.21% | 38.45% | -28.46% | -30.59% | 41.77% |
| SG&A Expenses | 4.42% | -29.95% | -28.66% | -26.89% | 82.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.93% | -34.75% | -26.50% | -24.21% | -9.33% |
| Operating Income | 23.80% | 34.75% | 26.23% | 23.97% | 8.52% |
| Income Before Tax | 57.91% | 82.99% | 50.73% | 48.14% | 14.44% |
| Income Tax Expenses | 133.33% | -279.89% | 76.86% | 74.35% | -1.75% |
| Earnings from Continuing Operations | 57.33% | 85.29% | 50.56% | 47.97% | 14.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.33% | 85.29% | 50.56% | 47.97% | 14.55% |
| EBIT | 23.80% | 34.75% | 26.23% | 23.97% | 8.52% |
| EBITDA | 24.72% | 35.83% | 27.10% | 23.36% | 9.08% |
| EPS Basic | 76.78% | 91.89% | 57.58% | 57.58% | -136,123.08% |
| Normalized Basic EPS | 77.09% | 91.30% | 40.00% | 35.00% | -133,732.00% |
| EPS Diluted | 76.78% | 91.89% | 57.58% | 57.58% | -136,123.08% |
| Normalized Diluted EPS | 77.09% | 91.30% | 40.00% | 35.00% | -133,732.00% |
| Average Basic Shares Outstanding | 83.74% | 87.71% | 18.96% | 18.96% | -99.94% |
| Average Diluted Shares Outstanding | 83.74% | 87.71% | 18.96% | 18.96% | -99.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
